Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."

TSX:TST - Post Discussion

TELESTA THERAPEUTICS INC > FDA adcom transcript - take two
View:
Post by Xiawen13 on Mar 13, 2016 10:13pm

FDA adcom transcript - take two

I think the reason why we are sitting at 66% cash value is that most investor s havent read the adcom transcrip. People just read the headline "FDA reject mcna" and so, people
deemed it doomed.

but when you read the adcom transcript, a significant number of experts (some of them ending up votinh no) suggested Mcna could well be a better first line therapy than bcg.

its not just anecdotical. From page 200 on, this idea keeps coming back.

So if FDA annonce a plan to try mcna on bcg naive patient, we would be looking at a completly other market. We would instantly become a Phase III company with a serious shot at becoming the new first line therapy for bladder cancer.

To be honest, I prefer that scenario much more than an other second line treatent phase IIi trial trying to find biomarker for what could end up to be a smaller client population
Comment by specul8tor on Mar 14, 2016 9:20am
Best post in weeks....Well said..
Comment by cheetio on Mar 14, 2016 11:18am
jeez............still a few live corpses strolling around the graveyard
Comment by zakmirza on Mar 14, 2016 11:52am
Rip Van Winkle just came out of his slumber with a delusion! SP is where it should be, no wait  it should be at 5cents. 40 for 1 is coming followed by massive dilution.
Comment by specul8tor on Mar 14, 2016 12:20pm
I completely disagree with your views zakmirza..I don't know wtf is going on,but last week house 7 was the main seller.Today they are buying heavy from anon house 1 and I also notice house 33 is also buying which usually means good things are not far off..I think someone(s) trying to accumulate at .095..We will soon find out why..all just my opinion....
Comment by Xiawen13 on Mar 14, 2016 12:24pm
There will be dilution only if we have a new partner, which means we will be on track for a new phase III, therefore not selling the assets. You call that bad news?
Comment by specul8tor on Mar 14, 2016 12:28pm
A share rollback is always bad news imo.I haven't seen one go well yet.However I don't see that happening here as TST still has lots of capital.I would not be suprised to see it taken out as it is now trading at a large discount to cash....
Comment by Xiawen13 on Mar 14, 2016 1:24pm
summer 2015: TST issue 100MIL shares at .34 autumn 2015: shares climbed to .90
Comment by higgsboson on Mar 14, 2016 1:38pm
zak    mirza    where the nhell did you get that name     judging from your posts on TST you must be heavily in the RED     also as in lipstick 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities